NASDAQ:GLPG - Galapagos Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $67.25
  • Forecasted Upside: 23.55 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.16 (2.18%)

This chart shows the closing price for GLPG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galapagos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLPG

Analyst Price Target is $67.25
▲ +23.55% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Galapagos in the last 3 months. The average price target is $67.25, with a high forecast of $79.00 and a low forecast of $55.00. The average price target represents a 23.55% upside from the last price of $54.43.

This chart shows the closing price for GLPG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 contributing investment analysts is to hold stock in Galapagos. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 10 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2022Royal Bank of CanadaLower Price Target$62.00 ➝ $55.00Low
7/25/2022Jefferies Financial GroupDowngradeHold ➝ UnderperformLow
7/15/2022Morgan StanleyLower Price TargetOverweight$80.00 ➝ $79.00Low
5/12/2022UBS GroupBoost Price TargetNeutral ➝ Neutral€52.00 ➝ €70.00High
5/12/2022JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral€60.00 ➝ €65.00High
2/28/2022Morgan StanleyBoost Price TargetOverweight$77.00 ➝ $80.00Medium
1/28/2022Bryan, Garnier & CoUpgradeSell ➝ BuyHigh
1/27/2022CitigroupUpgradeNeutral ➝ BuyHigh
1/6/2022Morgan StanleyLower Price TargetOverweight$118.00 ➝ $77.00Low
11/8/2021Royal Bank of CanadaBoost Price TargetSector Perform$64.00 ➝ $65.00Low
8/27/2021UBS GroupReiterated RatingNeutralLow
8/19/2021BarclaysDowngradeOverweight ➝ Equal WeightHigh
8/11/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/9/2021Royal Bank of CanadaLower Price TargetSector Perform$87.00 ➝ $64.00Low
8/6/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$50.00Low
7/15/2021Raymond JamesSet Price TargetBuy$65.80High
6/7/2021BarclaysReiterated RatingOverweightLow
5/11/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
5/10/2021Morgan StanleyBoost Price TargetOverweight$117.00 ➝ $118.00High
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
4/14/2021BarclaysUpgradeEqual Weight ➝ OverweightLow
4/12/2021UBS GroupReiterated RatingNeutralMedium
3/11/2021Morgan StanleyLower Price TargetOverweight$129.00 ➝ $117.00Low
3/2/2021BarclaysReiterated RatingEqual WeightLow
2/25/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$100.00Low
2/23/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$93.00 ➝ $94.00Low
2/19/2021Raymond JamesUpgradeMarket Perform ➝ OutperformLow
2/11/2021UBS GroupReiterated RatingNeutralLow
2/11/2021CitigroupDowngradeBuy ➝ NeutralLow
2/10/2021Maxim GroupDowngradeBuy ➝ HoldLow
1/19/2021BarclaysBoost Price TargetEqual Weight$85.50 ➝ $125.00Low
1/19/2021Morgan StanleyUpgradeEqual Weight ➝ OverweightMedium
12/17/2020Maxim GroupLower Price Target$140.00 ➝ $170.00High
12/17/2020Smith Barney CitigroupReiterated RatingBuyHigh
12/17/2020Bryan, Garnier & CoDowngradeBuy ➝ SellHigh
11/23/2020UBS GroupReiterated RatingNeutralLow
11/19/2020Maxim GroupInitiated CoverageBuy$170.00Low
11/12/2020JPMorgan Chase & Co.Lower Price TargetNeutral$152.00 ➝ $142.00Medium
10/21/2020The Goldman Sachs GroupDowngradeNeutral ➝ SellLow
10/16/2020UBS GroupReiterated RatingNeutralLow
10/16/2020Royal Bank of CanadaLower Price TargetSector Perform$135.00 ➝ $131.00High
10/13/2020BarclaysReiterated RatingEqual WeightLow
10/13/2020Morgan StanleyBoost Price TargetEqual Weight$158.00 ➝ $159.00Low
10/8/2020UBS GroupReiterated RatingNeutralLow
9/25/2020Stifel NicolausReiterated RatingHoldLow
9/24/2020JPMorgan Chase & Co.Reiterated RatingNeutralMedium
9/11/2020Stifel NicolausReiterated RatingHoldLow
8/25/2020Jefferies Financial GroupDowngradeBuy ➝ HoldLow
8/24/2020HC WainwrightDowngradeBuy ➝ Neutral$270.00 ➝ $123.00Low
8/21/2020Morgan StanleyLower Price TargetEqual Weight$221.00 ➝ $158.00Low
8/21/2020Bank of AmericaLower Price TargetUnderperform$148.00 ➝ $134.00Low
8/19/2020CitigroupUpgradeNeutral ➝ BuyHigh
8/19/2020Cantor FitzgeraldLower Price TargetNeutral$192.00 ➝ $134.00High
8/19/2020BarclaysDowngradeOverweight ➝ Equal WeightHigh
8/18/2020Stifel NicolausReiterated RatingHold$155.00High
8/11/2020BarclaysReiterated RatingOverweightMedium
8/10/2020Morgan StanleyLower Price TargetEqual Weight$224.00 ➝ $221.00Low
8/7/2020Stifel NicolausReiterated RatingHold$187.00High
7/24/2020HC WainwrightReiterated RatingBuy$270.00Low
7/15/2020Morgan StanleyLower Price TargetEqual Weight$226.00 ➝ $224.00Low
7/10/2020Stifel NicolausDowngradeBuy ➝ Hold$298.00 ➝ $193.00High
5/21/2020NomuraReiterated RatingBuy$290.00Medium
5/21/2020HC WainwrightLower Price TargetBuy$302.00 ➝ $270.00High
5/18/2020UBS GroupReiterated RatingNeutralMedium
5/15/2020BarclaysReiterated RatingOverweightLow
4/15/2020Morgan StanleyBoost Price TargetEqual Weight$220.00 ➝ $226.00Low
4/13/2020Royal Bank of CanadaReiterated RatingHold$155.00Low
3/30/2020Jefferies Financial GroupUpgradeHold ➝ Buy$232.00Low
3/18/2020Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform$175.00 ➝ $157.00Low
3/2/2020JPMorgan Chase & Co.Lower Price TargetNeutral$205.00 ➝ $200.00High
2/26/2020Morgan StanleyBoost Price TargetEqual Weight$215.00 ➝ $220.00Low
2/26/2020Nomura SecuritiesReiterated RatingBuy$209.00 ➝ $290.00Low
2/25/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$187.00 ➝ $192.00High
2/24/2020HC WainwrightReiterated RatingBuy$205.00 ➝ $302.00High
2/24/2020CitigroupDowngradeNeutral ➝ Underperform$213.00High
2/24/2020Stifel NicolausReiterated RatingBuy$188.00 ➝ $298.00High
2/24/2020Bank of AmericaDowngradeNeutral ➝ Underperform$213.00High
2/20/2020Royal Bank of CanadaDowngradeSector Perform ➝ Underperform$175.00High
1/5/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$205.00N/A
12/20/2019UBS GroupDowngradeBuy ➝ NeutralLow
12/18/2019CitigroupDowngradeBuy ➝ NeutralLow
12/17/2019Morgan StanleyDowngradeOverweight ➝ Equal$193.00 ➝ $215.00Low
12/13/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$174.00 ➝ $169.00Medium
12/2/2019Bank of AmericaInitiated CoverageNeutral$199.00Low
11/15/2019Royal Bank of CanadaBoost Price TargetSector Perform$152.00 ➝ $158.00Low
10/29/2019Morgan StanleyLower Price TargetOverweight$193.00Low
9/9/2019Morgan StanleyInitiated CoverageOverweight$200.00Medium
7/31/2019UBS GroupUpgradeNeutral ➝ BuyLow
7/29/2019Nomura SecuritiesBoost Price TargetBuy$140.00 ➝ $209.00Medium
7/29/2019Royal Bank of CanadaBoost Price Target$171.00Low
7/29/2019Jefferies Financial GroupDowngradeBuy ➝ HoldLow
7/26/2019CowenReiterated RatingBuyLow
7/15/2019Raymond JamesDowngradeStrong-Buy ➝ Market PerformLow
7/15/2019Stifel NicolausBoost Price TargetBuy$121.00 ➝ $188.00High
7/15/2019HC WainwrightBoost Price TargetBuy ➝ Buy$150.00 ➝ $205.00High
7/10/2019Credit Suisse GroupReiterated RatingOutperformLow
7/2/2019HC WainwrightSet Price TargetBuy$150.00Low
6/12/2019HC WainwrightReiterated RatingBuy$150.00Low
5/23/2019HC WainwrightSet Price TargetBuy$150.00Low
5/2/2019Cantor FitzgeraldReiterated RatingBuy$130.00Low
4/29/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$138.00 ➝ $139.00Low
4/26/2019Cantor FitzgeraldSet Price TargetBuy$130.00Low
3/29/2019HC WainwrightBoost Price TargetPositive$150.00Low
3/28/2019HC WainwrightInitiated CoverageBuy ➝ Buy$136.00 ➝ $136.00Low
3/26/2019Cantor FitzgeraldSet Price TargetBuy$130.00Medium
2/22/2019CowenReiterated RatingBuyLow
2/22/2019SVB LeerinkInitiated CoverageOutperform$140.00Low
12/19/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$130.00Medium
12/13/2018Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
11/14/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$157.00Low
11/5/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$127.00 ➝ $131.00Low
10/30/2018Nomura SecuritiesBoost Price TargetBuy ➝ Buy$124.00 ➝ $140.00Low
10/26/2018Credit Suisse GroupLower Price TargetNeutral ➝ Hold$92.00 ➝ $90.00Low
9/12/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$140.00High
9/12/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$109.00 ➝ $111.00High
8/17/2018The Goldman Sachs GroupReiterated RatingNeutralLow
8/9/2018The Goldman Sachs GroupDowngradeBuy ➝ NeutralMedium
8/7/2018Credit Suisse GroupSet Price TargetNeutral ➝ Hold$85.00 ➝ $92.00Low
8/6/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$126.00 ➝ $127.00Low
7/13/2018Morgan StanleyBoost Price TargetOverweight$125.00 ➝ $126.00Low
6/29/2018Royal Bank of CanadaLower Price TargetSector Perform$94.00High
6/29/2018Stifel NicolausLower Price TargetBuy ➝ Buy$120.00 ➝ $109.00High
5/31/2018CowenReiterated RatingBuyLow
4/29/2018BTIG ResearchReiterated RatingBuy$118.00Low
2/8/2018BTIG ResearchReiterated RatingBuy$118.00High
11/20/2017BTIG ResearchReiterated RatingBuy$118.00N/A
10/29/2017Stifel NicolausReiterated RatingBuy$120.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$92.00 ➝ $123.00N/A
9/15/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$101.00 ➝ $120.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$98.00Medium
8/11/2017Nomura SecuritiesBoost Price TargetBuy$108.00 ➝ $124.00Low
8/11/2017Stifel NicolausUpgradeHold ➝ Buy$83.00 ➝ $101.00Medium
8/10/2017Morgan StanleyReiterated RatingOverweight$92.00Medium
8/10/2017CowenReiterated RatingBuyMedium
(Data available from 8/10/2017 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 6 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 6 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Galapagos logo
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Read More

Today's Range

Now: $54.43
Low: $53.82
High: $54.43

50 Day Range

MA: $54.70
Low: $50.91
High: $57.79

52 Week Range

Now: $54.43
Low: $46.41
High: $72.11


1,872 shs

Average Volume

317,084 shs

Market Capitalization

$3.58 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Galapagos?

The following sell-side analysts have issued stock ratings on Galapagos in the last twelve months: Barclays PLC, Bryan, Garnier & Co, Citigroup Inc., Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada,, and UBS Group AG.
View the latest analyst ratings for GLPG.

What is the current price target for Galapagos?

4 Wall Street analysts have set twelve-month price targets for Galapagos in the last year. Their average twelve-month price target is $67.25, suggesting a possible upside of 26.2%. Morgan Stanley has the highest price target set, predicting GLPG will reach $79.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $55.00 for Galapagos in the next year.
View the latest price targets for GLPG.

What is the current consensus analyst rating for Galapagos?

Galapagos currently has 1 sell rating, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GLPG, but not buy more shares or sell existing shares.
View the latest ratings for GLPG.

What other companies compete with Galapagos?

How do I contact Galapagos' investor relations team?

Galapagos' physical mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company's listed phone number is (321) 534-2900 and its investor relations email address is [email protected] The official website for Galapagos is Learn More about contacing Galapagos investor relations.